DLin-MC3-DMA Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

ionizable amino lipid compound Reference needs_revision Best effort · source review pending

Also known as: MC3, MC-3, DLin-M-C3-DMA, D-Lin-MC3-DMA, dilinoleylmethyl-4-dimethylaminobutyrate, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Best-Effort Research Profile

DLin-MC3-DMA, commonly abbreviated MC3, is an ionizable amino lipid containing two linoleyl-derived unsaturated hydrocarbon chains and a dimethylaminobutanoate head group. It is used in lipid nanoparticles for delivery of siRNA and other nucleic-acid cargos and is the ionizable lipid component of the approved patisiran lipid complex formulation.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Administration Routes (Research)

intravenous, as a component of the patisiran lipid complex formulationintravenous, as a component of experimental lipid nanoparticlesintramuscular, as a component of experimental lipid nanoparticles

Reported Research Effects

Supports encapsulation and intracellular delivery of nucleic-acid cargos when incorporated into lipid nanoparticles.
Enables pH-responsive lipid nanoparticle behavior and endosomal delivery of siRNA in experimental formulations.
In optimized siRNA lipid nanoparticles, formulations containing DLin-MC3-DMA produced hepatic gene silencing in mouse and nonhuman-primate studies.
In the approved patisiran lipid complex, DLin-MC3-DMA is used with DSPC, cholesterol, and PEG2000-C-DMG as structural lipid components.

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

DLin-MC3-DMA was identified through optimization of ionizable lipids for hepatic siRNA delivery. The 2012 Jayaraman study reported an optimized lipid nanoparticle formulation containing 50 mol% DLin-MC3-DMA and described an siRNA ED50 of approximately 0.005 mg/kg in mice and less than 0.03 mg/kg in cynomolgus monkeys; these are study-level siRNA payload doses, not standalone DLin-MC3-DMA doses. The same study associated high delivery activity with an ionizable-lipid pKa range of approximately 6.2-6.5 and reported a pKa of approximately 6.44 for MC3. The common MC3 lipid nanoparticle composition is DLin-MC3-DMA/DSPC/cholesterol/PEG-lipid at approximately 50:10:38.5:1.5 mol%, although composition varies by study. The current U.S. product labeling for ONPATTRO lists 13.0 mg/mL DLin-MC3-DMA in the lipid complex. No standalone compound half-life, onset, solubility, or storage specification was established from the authoritative sources reviewed.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

PubChem CID 49785164; CAS RN 1224606-06-7; molecular formula C43H79NO2; molecular weight 642.1 g/mol; InChIKey NRLNQCOGCKAESA-KWXKLSQISA-N; IUPAC name [(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate

Source-Backed Observations

The compound is generally described in the literature as an ionizable or pH-sensitive cationic lipid rather than as a permanently charged cationic lipid. PubChem reports the listed molecular descriptors as computed properties.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Dlin-MC3-DMA, PubChem Compound Summary, CID 49785164
https://pubchem.ncbi.nlm.nih.gov/compound/Dlin-mc3-dma (accessed 2026-09-10)

ONPATTRO (patisiran) Prescribing Information
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e87ec36f-b4b4-49d4-aea4-d4ffb09b0970 (accessed 2026-09-10)

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
https://pubmed.ncbi.nlm.nih.gov/22782619/ (accessed 2026-09-10)

Onpattro, INN-patisiran: European Public Assessment Report
https://www.ema.europa.eu/en/documents/assessment-report/onpattro-epar-public-assessment-report_en.pdf (accessed 2026-09-10)

Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration
https://pmc.ncbi.nlm.nih.gov/articles/PMC8358000/ (accessed 2026-09-10)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.